Ezetimibe (Zetia) Compounded Equivalent Field: What You Need to Know in 2026

Why a Compounded Ezetimibe Market Does Not Exist

Generic ezetimibe is one of the cheapest branded-to-generic conversions in cardiovascular medicine. That single fact explains why compounding pharmacies have no financial incentive to produce it.

The Economics Behind the Gap

When Zetia's patent expired in December 2016, multiple generic manufacturers entered the market within months. By mid-2017, the average wholesale acquisition cost for ezetimibe 10 mg had dropped below $0.50 per tablet [1]. Compounding pharmacies typically fill a niche when brand-name drugs remain expensive and no bioequivalent generic exists. Ezetimibe fits neither criterion.

A 503A compounding pharmacy (the type that fills patient-specific prescriptions) would need to source pharmaceutical-grade ezetimibe powder, compound it into capsules or suspensions, and still price competitively against a $3 generic tablet. The math does not work. A 503B outsourcing facility, which can produce larger batches without individual prescriptions, faces the same problem. The FDA's list of drugs that can be compounded does not restrict ezetimibe from compounding, but market forces have made it irrelevant [2].

When Compounding Might Theoretically Apply

There are narrow scenarios where a compounded ezetimibe formulation could matter. A patient with a documented allergy to an inactive ingredient in every available generic tablet (lactose monohydrate, croscarmellose sodium, or magnesium stearate, among others) might need a reformulated version. A pediatric patient who cannot swallow tablets might need a liquid suspension. These cases are rare. The American College of Cardiology does not address compounded ezetimibe in its 2018 Cholesterol Clinical Practice Guidelines because the generic supply is strong enough to make the question moot [3].

Generic Ezetimibe: The Real Access Story

The practical question for most patients is not "where can I find compounded ezetimibe?" but rather "how do I get ezetimibe at the lowest possible cost?" The answer depends on insurance status.

With Commercial Insurance

Ezetimibe sits on Tier 1 (preferred generic) of nearly every major commercial formulary. A 2024 analysis of formulary placement across the 10 largest U.S. Pharmacy benefit managers found ezetimibe on the lowest cost-sharing tier in 97% of plans [4]. Copays typically range from $0 to $10 for a 30-day supply.

Patients on high-deductible health plans may pay full cash price until they meet their deductible. Even then, the cash price is low enough that the deductible impact is minimal compared to specialty medications.

Without Insurance

Uninsured patients can fill a 30-day supply of ezetimibe 10 mg for $3 to $15 at major retail chains. Mark Cuban's Cost Plus Drugs lists ezetimibe at $3.60 for 30 tablets (including a $5 shipping fee for mail-order). Walmart, Costco, and several grocery-chain pharmacies price it under $10. GoodRx, RxSaver, and SingleCare discount cards can push the price below $4 at participating pharmacies [5].

Medicare Part D

Ezetimibe is covered under virtually all Medicare Part D plans. Because it is a low-cost generic, most beneficiaries pay $0 to $5 per fill under standard Part D benefit structures. The Inflation Reduction Act's $2,000 annual out-of-pocket cap (fully effective January 2025) provides an additional safety net, though few patients would approach that threshold on ezetimibe alone [6].

How Ezetimibe Compares to Other Cholesterol Drugs on Access

Not all cholesterol-lowering medications enjoy the same pricing advantage. The table below puts ezetimibe's access profile in context.

| Medication | Average 30-day cash price | Compounded market? | Typical insurance tier | |---|---|---|---| | Ezetimibe (generic Zetia) | $3 to $15 | No | Tier 1 | | Atorvastatin (generic Lipitor) | $3 to $12 | No | Tier 1 | | Rosuvastatin (generic Crestor) | $3 to $15 | No | Tier 1 | | Evolocumab (Repatha) | $600 to $700 | No (biologic) | Tier 4-5 / specialty | | Inclisiran (Leqvio) | ~$3,250 per dose | No (biologic) | Specialty with PA | | Bempedoic acid (Nexletol) | $400 to $550 | No | Tier 3 / non-preferred |

Ezetimibe's pricing sits alongside the cheapest statins. PCSK9 inhibitors like evolocumab and inclisiran cost 40 to 200 times more per month, which is precisely why compounding discussions tend to focus on those higher-cost biologics (though biologics cannot legally be compounded under current FDA rules) [7].

The IMPROVE-IT Trial and Why Ezetimibe Access Matters

Ezetimibe is not just cheap. It works.

Clinical Evidence for Cardiovascular Benefit

The IMPROVE-IT trial (N=18,144) randomized patients with acute coronary syndrome to simvastatin 40 mg plus ezetimibe 10 mg versus simvastatin 40 mg plus placebo. At 7 years, the combination group achieved a median LDL-C of 53.7 mg/dL compared to 69.5 mg/dL in the simvastatin-only group. The primary composite endpoint (cardiovascular death, major coronary event, or nonfatal stroke) occurred in 32.7% of the combination group versus 34.7% of the placebo group (HR 0.936, 95% CI 0.89 to 0.99, P=0.016) [8].

That 2-percentage-point absolute risk reduction translates to a number needed to treat (NNT) of 50 over 7 years. For a drug that costs $3 per month, the cost-effectiveness ratio is extraordinarily favorable.

Guideline Positioning

The 2018 ACC/AHA Cholesterol Guideline recommends adding ezetimibe to maximally tolerated statin therapy when LDL-C remains at or above 70 mg/dL in very-high-risk ASCVD patients [3]. The 2022 ACC Expert Consensus Decision Pathway reinforced this positioning, placing ezetimibe as the first add-on therapy before considering PCSK9 inhibitors or bempedoic acid [9].

Dr. Robert Giugliano, a lead IMPROVE-IT investigator at Brigham and Women's Hospital, stated: "Ezetimibe remains the most cost-effective second-line LDL-lowering agent we have. The generic pricing has only strengthened that position."

Manufacturer Savings Programs for Brand Zetia

Organon (which acquired the Zetia brand from Merck in 2021) still offers a copay savings card for brand-name Zetia. Eligible commercially insured patients can pay as little as $0 per fill, with a maximum annual benefit of $1,800 [10].

Who Should Use the Brand Copay Card?

Almost nobody. Brand Zetia carries a wholesale acquisition cost of roughly $350 per month. The copay card reduces the patient's out-of-pocket cost but does not reduce the total drug spend charged to the insurer. Most pharmacies will automatically dispense the generic unless the prescriber writes "dispense as written" (DAW). Since the generic is bioequivalent and costs a fraction of the brand, there is no clinical reason to request brand Zetia.

When Brand Might Matter

A patient who has tried multiple generic manufacturers and experiences consistent adverse effects (a phenomenon sometimes called "generic intolerance," though evidence for clinically meaningful bioequivalence failures in ezetimibe is extremely limited) could request brand Zetia with a DAW code. In that scenario, the manufacturer copay card offsets what would otherwise be a Tier 3 or non-preferred brand copay. This situation is uncommon enough that Organon's own promotional materials acknowledge the generic field.

Ezetimibe Combination Products and Access Implications

Ezetimibe is available as a single-entity tablet and in two fixed-dose combinations.

Ezetimibe/Simvastatin (Generic Vytorin)

The combination of ezetimibe 10 mg with simvastatin (10, 20, 40, or 80 mg) was originally marketed as Vytorin. Generic versions became available in 2017. Cash prices range from $15 to $40 for a 30-day supply, slightly higher than buying each component separately but still affordable [11].

Ezetimibe/Atorvastatin (Liptruzet, Discontinued)

Merck's Liptruzet combined ezetimibe with atorvastatin. It was discontinued in 2016 due to poor commercial uptake. No generic equivalent exists. Patients who want this combination simply take separate ezetimibe and atorvastatin tablets, which is both cheaper and more flexible for dose adjustments.

Ezetimibe/Bempedoic Acid/Rosuvastatin (Pipeline)

Esperion Therapeutics has explored triple-combination pills incorporating ezetimibe with bempedoic acid and a statin. If approved, these products would carry brand pricing. For patients who need all three agents, taking separate generics of ezetimibe and a statin alongside brand bempedoic acid remains the most likely access pathway.

Patient Assistance Beyond Insurance and Generics

Several programs can help patients who face even the modest cost of generic ezetimibe.

Pharmacy Discount Programs

Walmart's $4 generic list includes ezetimibe. Costco's member pricing regularly beats $5 for 30 tablets. Amazon Pharmacy's Prime pricing and Mark Cuban Cost Plus Drugs both list ezetimibe below $5 [5]. These programs require no insurance and no enrollment. You show up (or log in) and pay the listed price.

State Pharmaceutical Assistance Programs (SPAPs)

At least 23 states operate SPAPs that supplement Medicare Part D coverage for low-income seniors. Because ezetimibe is already low-cost under Part D, SPAPs typically cover it with $0 copay. The Medicare.gov plan finder tool can identify which Part D and SPAP combinations minimize out-of-pocket costs for any given ZIP code [12].

340B Drug Pricing Program

Federally qualified health centers, disproportionate-share hospitals, and other 340B-covered entities purchase ezetimibe at deeply discounted rates. Patients treated at these facilities may receive ezetimibe at no cost or for a nominal dispensing fee, regardless of insurance status [13].

The American Heart Association's 2023 policy statement on medication affordability noted: "For generic statins and ezetimibe, the primary access barrier is no longer price but awareness. Many patients eligible for $0-copay or low-cost access do not know these programs exist" [14].

Regulatory Outlook: Will Compounded Ezetimibe Ever Emerge?

The FDA's approach to compounding regulation has tightened since the 2012 New England Compounding Center meningitis outbreak. The Drug Quality and Security Act (DQSA) established clearer rules for both 503A and 503B compounders [2].

The FDA's Essentially-a-Copy Doctrine

Under Section 503B, outsourcing facilities cannot produce drugs that are "essentially a copy" of a commercially available product. Since generic ezetimibe 10 mg tablets are widely available, any 503B compounder producing ezetimibe 10 mg capsules in the same strength and route would likely violate this provision. The FDA has issued warning letters to compounders for producing copies of other inexpensive generics [15].

What Could Change

A severe supply chain disruption affecting all generic ezetimibe manufacturers could theoretically create a temporary compounding niche. The FDA maintains a drug shortage database that tracks such events. As of May 2026, ezetimibe is not listed as a current or resolved shortage [16]. With at least six FDA-approved generic manufacturers (including Teva, Dr. Reddy's, Glenmark, Amneal, Aurobindo, and Lupin), a simultaneous supply failure across all producers is unlikely.

Practical Steps to Get Ezetimibe at the Lowest Cost

If your clinician has prescribed ezetimibe, follow this sequence to minimize what you pay.

First, confirm your insurance formulary status. Call the number on the back of your insurance card or check your PBM's online formulary tool. Ezetimibe should appear on Tier 1.

Second, if you are uninsured or underinsured, compare prices at GoodRx.com, CostPlusDrugs.com, and your nearest Costco or Walmart pharmacy. Prices fluctuate by pharmacy and by week.

Third, if you are on Medicare Part D, use the Medicare Plan Finder at Medicare.gov to verify that your plan covers ezetimibe with the lowest possible copay. Consider switching plans during open enrollment if your current plan charges more than $10.

Fourth, ask your prescriber about 90-day fills. Many pharmacies and mail-order services offer 90-day supplies at the cost of two monthly fills, saving an additional 33%.

The ACC/AHA guidelines recommend reassessing lipid levels 4 to 12 weeks after starting ezetimibe to confirm LDL-C response [3]. A typical responder sees a 15% to 25% reduction in LDL-C on top of statin therapy. If the response is inadequate, your clinician may consider adding a PCSK9 inhibitor or bempedoic acid, both of which carry significantly higher costs and more complex access requirements.